Mouwasat H1 2024 profit rises 2% to SAR 324.3M; Q2 at SAR 152.7M

Mouwasat Medical Services Co. reported a net profit of SAR 324.3 million for the first half of 2024, up 2% compared to SAR 317.2 million in the prior-year period.

Financials (M)

Item	6m 2023	6m 2024	Change‬
Revenues	1,291.56	1,413.08	9.4 %
Gross Income	621.42	653.26	5.1 %
Operating Income	365.26	368.01	0.8 %
Net Income	317.15	324.28	2.2 %
Average Shares	200.00	200.00	-
EPS (Riyals)	1.59	1.62	2.2 %

Revenues increased by 9.4% year-on-year (YoY) to SAR 1.41 billion, boosted by a rise in the number of outpatient visits and occupancy rates in inpatient departments on the launch of the Mouwasat Center in Madinah as of January 2024.

The company also cited improved contractual terms with customers and continued performance improvement of specialized resources in the company’s hospitals. This is in addition to the continuous enhancement of operating efficiency of the available resources.

The cost of financing declined in H1 2024 due to a lower balance of loans by the amount of installments repaid during the period.

In Q2 2024, net profit rose 1.4% to SAR 152.7 million from SAR 150.5 million a year earlier, as revenues increased by 10% YoY to SAR 690 million due to a rise in the number of outpatient visits and occupancy rates in inpatient departments on the launch of the Mouwasat Center in Madinah as of January 2024.

When compared to Q1 2024, net profit saw an 11% decline from SAR 171.58 million.

Current Quarter Comparison (M)

Compared With The

Item	Q2 2023	Q2 2024	Change‬
Revenues	627.34	690.30	10.0 %
Gross Income	293.03	307.43	4.9 %
Operating Income	172.27	176.20	2.3 %
Net Income	150.54	152.70	1.4 %
Average Shares	200.00	200.00	-
EPS (Riyals)	0.75	0.76	1.4 %

Item	Q1 2024	Q2 2024	Change‬
Revenues	722.78	690.30	(4.5 %)
Gross Income	345.83	307.43	(11.1 %)
Operating Income	192.50	176.20	(8.5 %)
Net Income	171.58	152.70	(11.0 %)
Average Shares	200.00	200.00	-
EPS (Riyals)	0.86	0.76	(11.0 %)

Total shareholders’ equity, after minority interest, reached SAR 3.25 billion as of June 30, 2024, compared with SAR 2.93 billion a year earlier.

View More Financial Results

View other reports

Share Price

Mouwasat Medical Services Co. (MOUWASAT)

	Current
Market Cap (M Riyal)	18,880.00
Enterprise Value (EV) (M)	19,700.65
Shares Outstanding ((M))	200.00
EPS ( Riyal) (TTM)	3.29
Book Value (BV) ( Riyal)	17.66
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	28.69
P/E (TTM)	28.69
Price/book	5.34
Return on Average Assets (%) (TTM)	13.0
Return on Average Equity (%) (TTM)	19.9

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2015	253.41	4.1 %	118.63	(4.5 %)	62.06	(1.4 %)
Q2 2015	255.10	4.4 %	115.78	(6.7 %)	63.05	(0.3 %)
Q3 2015	231.63	0.5 %	98.68	(12.7 %)	49.14	(9.2 %)
Q4 2015	259.94	5.2 %	113.72	(3.2 %)	60.66	14.8 %
2015	1,000.08	10.7 %	446.81	7.1 %	234.90	0.7 %
Q1 2016	303.59	19.8 %	143.50	21.0 %	75.66	21.9 %
Q2 2016	300.21	17.7 %	139.76	20.7 %	71.70	13.7 %
Q3 2016	280.24	21.0 %	124.29	26.0 %	56.32	14.6 %
Q4 2016	359.19	38.2 %	168.91	48.5 %	84.39	39.1 %
2016	1,243.22	24.3 %	576.45	29.0 %	288.06	22.6 %
Q1 2017	362.97	19.6 %	173.37	20.8 %	93.17	23.1 %
Q2 2017	353.24	17.7 %	163.53	17.0 %	84.18	17.4 %
Q3 2017	359.47	28.3 %	164.38	32.3 %	85.84	52.4 %
Q4 2017	431.45	20.1 %	210.90	24.9 %	108.35	28.4 %
2017	1,507.14	21.2 %	712.17	23.5 %	371.53	29.0 %
Q1 2018	422.35	16.4 %	199.84	15.3 %	116.20	24.7 %
Q2 2018	394.35	11.6 %	185.90	13.7 %	98.77	17.3 %
Q3 2018	404.27	12.5 %	182.64	11.1 %	90.46	5.4 %
Q4 2018	456.04	5.7 %	205.12	(2.7 %)	98.62	(9.0 %)
2018	1,677.02	11.3 %	773.50	8.6 %	404.06	8.8 %
Q1 2019	462.62	9.5 %	211.32	5.7 %	122.04	5.0 %
Q2 2019	446.26	13.2 %	194.20	4.5 %	104.04	5.3 %
Q3 2019	443.29	9.7 %	193.64	6.0 %	104.74	15.8 %
Q4 2019	505.04	10.7 %	230.11	12.2 %	139.67	41.6 %
2019	1,857.21	10.7 %	829.27	7.2 %	470.49	16.4 %
Q1 2020	493.94	6.8 %	220.55	4.4 %	122.98	0.8 %
Q2 2020	468.43	5.0 %	219.01	12.8 %	131.19	26.1 %
Q3 2020	549.06	23.9 %	271.52	40.2 %	173.32	65.5 %
Q4 2020	533.60	5.7 %	249.21	8.3 %	150.35	7.6 %
2020	2,045.03	10.1 %	960.30	15.8 %	577.84	22.8 %
Q1 2021	534.12	8.1 %	254.30	15.3 %	158.49	28.9 %
Q2 2021	526.71	12.4 %	246.46	12.5 %	154.77	18.0 %
Q3 2021	530.98	(3.3 %)	244.40	(10.0 %)	150.10	(13.4 %)
Q4 2021	552.33	3.5 %	250.62	0.6 %	158.56	5.5 %
2021	2,144.14	4.8 %	995.78	3.7 %	621.93	7.6 %
Q1 2022	566.97	6.1 %	267.78	5.3 %	159.68	0.8 %
Q2 2022	557.86	5.9 %	258.09	4.7 %	155.34	0.4 %
Q3 2022	549.15	3.4 %	247.06	1.1 %	139.25	(7.2 %)
Q4 2022	660.14	19.5 %	328.64	31.1 %	211.45	33.4 %
2022	2,334.11	8.9 %	1,101.57	10.6 %	665.72	7.0 %
Q1 2023	664.22	17.2 %	328.39	22.6 %	192.98	20.9 %
Q2 2023	627.34	12.5 %	293.03	13.5 %	172.27	10.9 %
Q3 2023	640.89	16.7 %	298.26	20.7 %	182.40	31.0 %
Q4 2023	773.06	17.1 %	394.57	20.1 %	201.69	(4.6 %)
2023	2,705.51	15.9 %	1,313.08	19.2 %	748.18	12.4 %
Q1 2024	722.78	8.8 %	345.83	5.3 %	192.50	(0.3 %)
Q2 2024	690.30	10.0 %	307.43	4.9 %	176.20	2.3 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2014	903.79	0.2 %	417.17	(8.5 %)	233.17	4.9 %
2015	1,000.08	10.7 %	446.81	7.1 %	234.90	0.7 %
2016	1,243.22	24.3 %	576.45	29.0 %	288.06	22.6 %
2017	1,507.14	21.2 %	712.17	23.5 %	371.53	29.0 %
2018	1,677.02	11.3 %	773.50	8.6 %	404.06	8.8 %
2019	1,857.21	10.7 %	829.27	7.2 %	470.49	16.4 %
2020	2,045.03	10.1 %	960.30	15.8 %	577.84	22.8 %
2021	2,144.14	4.8 %	995.78	3.7 %	621.93	7.6 %
2022	2,334.11	8.9 %	1,101.57	10.6 %	665.72	7.0 %
2023	2,705.51	15.9 %	1,313.08	19.2 %	748.18	12.4 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
Q1 2015	55.93	(3.5 %)	0.28	-	55.93	0.28
Q2 2015	56.09	(5.6 %)	0.28	-	56.09	0.28
Q3 2015	42.99	(40.3 %)	0.21	-	42.99	0.21
Q4 2015	53.80	6.0 %	0.27	-	53.80	0.27
2015	208.80	(13.0 %)	1.04	-	208.80	1.04
Q1 2016	68.47	22.4 %	0.34	-	68.47	0.34
Q2 2016	63.70	13.6 %	0.32	-	63.70	0.32
Q3 2016	49.36	14.8 %	0.25	-	49.36	0.25
Q4 2016	75.65	40.6 %	0.38	-	75.65	0.38
2016	257.18	23.2 %	1.29	-	257.18	1.29
Q1 2017	85.12	24.3 %	0.43	-	85.12	0.43
Q2 2017	76.34	19.8 %	0.38	-	76.34	0.38
Q3 2017	76.73	55.4 %	0.38	-	76.73	0.38
Q4 2017	98.55	30.3 %	0.49	-	98.55	0.49
2017	336.73	30.9 %	1.68	-	336.73	1.68
Q1 2018	106.01	24.5 %	0.53	-	106.01	0.53
Q2 2018	87.88	15.1 %	0.44	-	87.88	0.44
Q3 2018	80.89	5.4 %	0.40	-	80.89	0.40
Q4 2018	85.43	(13.3 %)	0.43	-	85.43	0.43
2018	360.21	7.0 %	1.80	-	360.21	1.80
Q1 2019	107.22	1.1 %	0.54	-	107.22	0.54
Q2 2019	90.31	2.8 %	0.45	-	90.31	0.45
Q3 2019	93.04	15.0 %	0.47	-	93.04	0.47
Q4 2019	130.47	52.7 %	0.65	-	130.47	0.65
2019	421.03	16.9 %	2.11	-	421.03	2.11
Q1 2020	108.03	0.8 %	0.54	-	108.03	0.54
Q2 2020	115.73	28.2 %	0.58	-	115.73	0.58
Q3 2020	161.10	73.2 %	0.81	-	161.10	0.81
Q4 2020	143.30	9.8 %	0.72	-	143.30	0.72
2020	528.16	25.4 %	2.64	-	528.16	2.64
Q1 2021	147.19	36.3 %	0.74	-	147.19	0.74
Q2 2021	141.35	22.1 %	0.71	-	141.35	0.71
Q3 2021	142.66	(11.4 %)	0.71	-	142.66	0.71
Q4 2021	146.97	2.6 %	0.73	-	146.97	0.73
2021	578.16	9.5 %	2.89	-	578.16	2.89
Q1 2022	150.21	2.1 %	0.75	-	150.21	0.75
Q2 2022	141.48	0.1 %	0.71	-	141.48	0.71
Q3 2022	122.21	(14.3 %)	0.61	-	122.21	0.61
Q4 2022	185.40	26.2 %	0.93	-	185.40	0.93
2022	599.31	3.7 %	3.00	-	599.31	3.00
Q1 2023	166.61	10.9 %	0.83	-	166.61	0.83
Q2 2023	150.54	6.4 %	0.75	-	150.54	0.75
Q3 2023	156.38	28.0 %	0.78	-	156.38	0.78
Q4 2023	184.17	(0.7 %)	0.92	-	184.17	0.92
2023	657.69	9.7 %	3.29	-	657.69	3.29
Q1 2024	171.58	3.0 %	0.86	-	171.58	0.86
Q2 2024	152.70	1.4 %	0.76	-	152.70	0.76

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
2014	240.12	19.3 %	1.20	23.90	216.22	1.08
2015	208.80	(13.0 %)	1.04	-	208.80	1.04
2016	257.18	23.2 %	1.29	-	257.18	1.29
2017	336.73	30.9 %	1.68	-	336.73	1.68
2018	360.21	7.0 %	1.80	-	360.21	1.80
2019	421.03	16.9 %	2.11	-	421.03	2.11
2020	528.16	25.4 %	2.64	-	528.16	2.64
2021	578.16	9.5 %	2.89	-	578.16	2.89
2022	599.31	3.7 %	3.00	-	599.31	3.00
2023	657.69	9.7 %	3.29	-	657.69	3.29

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2015	48.53 %	28.38 %	21.96 %
Q2 2015	47.14 %	28.23 %	21.38 %
Q3 2015	45.64 %	28.05 %	20.62 %
Q4 2015	44.68 %	28.92 %	20.88 %
2015	44.68 %	28.92 %	20.88 %
Q1 2016	44.91 %	29.32 %	21.08 %
Q2 2016	45.25 %	29.52 %	20.90 %
Q3 2016	45.57 %	29.40 %	20.57 %
Q4 2016	46.37 %	29.27 %	20.69 %
2016	46.37 %	29.27 %	20.69 %
Q1 2017	46.55 %	29.66 %	21.02 %
Q2 2017	46.48 %	29.75 %	21.13 %
Q3 2017	46.71 %	30.51 %	21.87 %
Q4 2017	47.25 %	30.73 %	22.34 %
2017	47.25 %	30.73 %	22.34 %
Q1 2018	47.15 %	31.21 %	22.83 %
Q2 2018	47.34 %	31.39 %	22.96 %
Q3 2018	47.16 %	30.90 %	22.59 %
Q4 2018	46.12 %	30.64 %	21.48 %
2018	46.12 %	30.64 %	21.48 %
Q1 2019	45.71 %	30.83 %	21.05 %
Q2 2019	44.84 %	30.84 %	20.57 %
Q3 2019	44.48 %	31.47 %	20.79 %
Q4 2019	44.65 %	33.14 %	22.67 %
2019	44.65 %	33.14 %	22.67 %
Q1 2020	44.40 %	32.62 %	22.34 %
Q2 2020	45.18 %	33.87 %	23.41 %
Q3 2020	46.68 %	35.60 %	25.56 %
Q4 2020	46.96 %	35.51 %	25.83 %
2020	46.96 %	35.51 %	25.83 %
Q1 2021	47.67 %	36.72 %	27.21 %
Q2 2021	47.66 %	36.83 %	27.66 %
Q3 2021	46.79 %	36.14 %	27.03 %
Q4 2021	46.44 %	36.35 %	26.96 %
2021	46.44 %	36.35 %	26.96 %
Q1 2022	46.36 %	35.98 %	26.70 %
Q2 2022	46.23 %	35.59 %	26.33 %
Q3 2022	45.98 %	35.37 %	25.19 %
Q4 2022	47.19 %	36.60 %	25.68 %
2022	47.19 %	36.60 %	25.68 %
Q1 2023	47.80 %	37.06 %	25.32 %
Q2 2023	47.87 %	37.24 %	24.98 %
Q3 2023	48.15 %	37.76 %	25.42 %
Q4 2023	48.58 %	35.96 %	24.31 %
2023	48.53 %	35.91 %	24.31 %
Q1 2024	48.18 %	35.38 %	23.97 %
Q2 2024	47.61 %	34.87 %	23.52 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2014	46.16 %	30.49 %	23.92 %
2015	44.68 %	28.92 %	20.88 %
2016	46.37 %	29.27 %	20.69 %
2017	47.25 %	30.73 %	22.34 %
2018	46.12 %	30.64 %	21.48 %
2019	44.65 %	33.14 %	22.67 %
2020	46.96 %	35.51 %	25.83 %
2021	46.44 %	36.35 %	26.96 %
2022	47.19 %	36.60 %	25.68 %
2023	48.53 %	35.91 %	24.31 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2015	46.81 %	29.28 %	22.07 %
Q2 2015	45.38 %	29.50 %	21.99 %
Q3 2015	42.60 %	27.19 %	18.56 %
Q4 2015	43.75 %	29.55 %	20.70 %
Q1 2016	47.27 %	30.60 %	22.55 %
Q2 2016	46.55 %	30.20 %	21.22 %
Q3 2016	44.35 %	27.12 %	17.62 %
Q4 2016	47.02 %	29.03 %	21.06 %
Q1 2017	47.76 %	31.79 %	23.45 %
Q2 2017	46.29 %	30.47 %	21.61 %
Q3 2017	45.73 %	30.75 %	21.34 %
Q4 2017	48.88 %	30.03 %	22.84 %
Q1 2018	47.32 %	33.44 %	25.10 %
Q2 2018	47.14 %	31.26 %	22.28 %
Q3 2018	45.18 %	28.81 %	20.01 %
Q4 2018	44.98 %	29.14 %	18.73 %
Q1 2019	45.68 %	33.91 %	23.18 %
Q2 2019	43.52 %	31.23 %	20.24 %
Q3 2019	43.68 %	31.56 %	20.99 %
Q4 2019	45.56 %	35.50 %	25.83 %
Q1 2020	44.65 %	31.90 %	21.87 %
Q2 2020	46.75 %	36.37 %	24.71 %
Q3 2020	49.45 %	38.37 %	29.34 %
Q4 2020	46.70 %	35.14 %	26.86 %
Q1 2021	47.61 %	36.88 %	27.56 %
Q2 2021	46.79 %	36.89 %	26.84 %
Q3 2021	46.03 %	35.66 %	26.87 %
Q4 2021	45.37 %	35.98 %	26.61 %
Q1 2022	47.23 %	35.41 %	26.49 %
Q2 2022	46.26 %	35.32 %	25.36 %
Q3 2022	44.99 %	34.77 %	22.25 %
Q4 2022	49.78 %	40.22 %	28.09 %
Q1 2023	49.44 %	37.27 %	25.08 %
Q2 2023	46.71 %	36.25 %	24.00 %
Q3 2023	46.54 %	37.22 %	24.40 %
Q4 2023	51.04 %	33.55 %	23.82 %
Q1 2024	47.85 %	34.71 %	23.74 %
Q2 2024	44.54 %	34.08 %	22.12 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2015	200.00	1.19	1.07	5.42
Q2 2015	200.00	1.17	1.05	5.20
Q3 2015	200.00	1.03	1.02	5.41
Q4 2015	200.00	1.04	1.04	5.67
Q1 2016	200.00	1.11	1.11	5.96
Q2 2016	200.00	1.14	1.14	5.84
Q3 2016	200.00	1.18	1.18	6.09
Q4 2016	200.00	1.29	1.29	6.38
Q1 2017	200.00	1.37	1.37	6.81
Q2 2017	200.00	1.43	1.43	6.57
Q3 2017	200.00	1.57	1.57	6.95
Q4 2017	200.00	1.68	1.68	7.45
Q1 2018	200.00	1.79	1.79	8.04
Q2 2018	200.00	1.85	1.85	7.73
Q3 2018	200.00	1.87	1.87	8.14
Q4 2018	200.00	1.80	1.80	8.56
Q1 2019	200.00	1.81	1.81	9.10
Q2 2019	200.00	1.82	1.82	8.68
Q3 2019	200.00	1.88	1.88	9.14
Q4 2019	200.00	2.11	2.11	9.78
Q1 2020	200.00	2.11	2.11	10.32
Q2 2020	200.00	2.24	2.24	9.90
Q3 2020	200.00	2.58	2.58	10.70
Q4 2020	200.00	2.64	2.64	11.40
Q1 2021	200.00	2.84	2.84	12.13
Q2 2021	200.00	2.96	2.96	11.59
Q3 2021	200.00	2.87	2.87	12.30
Q4 2021	200.00	2.89	2.89	13.02
Q1 2022	200.00	2.91	2.91	13.77
Q2 2022	200.00	2.91	2.91	13.10
Q3 2022	200.00	2.80	2.80	13.72
Q4 2022	200.00	3.00	3.00	14.61
Q1 2023	200.00	3.08	3.08	15.45
Q2 2023	200.00	3.12	3.12	14.70
Q3 2023	200.00	3.29	3.29	15.48
Q4 2023	200.00	3.29	3.29	16.39
Q1 2024	200.00	3.31	3.31	17.24
Q2 2024	200.00	3.32	3.32	16.26

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2014	200.00	1.20	1.08	5.14
2015	200.00	1.04	1.04	5.67
2016	200.00	1.29	1.29	6.38
2017	200.00	1.68	1.68	7.45
2018	200.00	1.80	1.80	8.56
2019	200.00	2.11	2.11	9.78
2020	200.00	2.64	2.64	11.40
2021	200.00	2.89	2.89	13.02
2022	200.00	3.00	3.00	14.61
2023	200.00	3.29	3.29	16.39

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2015	27.98	31.11	6.15
Q2 2015	30.38	33.83	6.86
Q3 2015	29.89	30.21	5.68
Q4 2015	29.17	29.17	5.37
Q1 2016	25.75	25.75	4.78
Q2 2016	28.12	28.12	5.51
Q3 2016	25.07	25.07	4.84
Q4 2016	28.74	28.74	5.79
Q1 2017	26.02	26.02	5.23
Q2 2017	27.61	27.61	6.02
Q3 2017	25.29	25.29	5.71
Q4 2017	22.48	22.48	5.08
Q1 2018	24.64	24.64	5.48
Q2 2018	25.46	25.46	6.08
Q3 2018	22.23	22.23	5.10
Q4 2018	22.35	22.35	4.70
Q1 2019	22.22	22.22	4.41
Q2 2019	24.74	24.74	5.19
Q3 2019	23.35	23.35	4.80
Q4 2019	20.90	20.90	4.50
Q1 2020	19.79	19.79	4.05
Q2 2020	20.19	20.19	4.56
Q3 2020	24.26	24.26	5.84
Q4 2020	26.13	26.13	6.05
Q1 2021	27.67	27.67	6.47
Q2 2021	30.39	30.39	7.78
Q3 2021	31.51	31.51	7.36
Q4 2021	30.06	30.06	6.67
Q1 2022	36.58	36.58	7.72
Q2 2022	36.64	36.64	8.13
Q3 2022	35.30	35.30	7.22
Q4 2022	34.87	34.87	7.15
Q1 2023	38.17	38.17	7.61
Q2 2023	38.73	38.73	8.23
Q3 2023	31.26	31.26	6.65
Q4 2023	34.00	34.00	6.82
Q1 2024	41.59	41.59	7.99
Q2 2024	36.46	36.46	7.46

Period	P/E	Adjusted P/E	Price/book
2014	25.71	28.55	6.01
2015	29.17	29.17	5.37
2016	28.74	28.74	5.79
2017	22.48	22.48	5.08
2018	22.35	22.35	4.70
2019	20.90	20.90	4.50
2020	26.13	26.13	6.05
2021	30.06	30.06	6.67
2022	34.87	34.87	7.15
2023	34.00	34.00	6.82

Business Segments (Million)

Compared With The

Period	Medical Services	Pharmaceutical Products	Administration Fees
Q1 2015	201.34	52.07	-
Q2 2015	205.21	49.89	-
Q3 2015	189.98	41.65	-
Q4 2015	213.59	46.36	-
Q1 2016	251.45	52.14	-
Q2 2016	250.70	49.51	-
Q3 2016	235.92	44.32	-
Q4 2016	306.32	52.87	-
Q1 2017	310.82	52.15	-
Q2 2017	301.62	51.62	-
Q3 2017	308.40	51.07	-
Q4 2017	368.74	62.71	-
Q1 2018	360.78	61.57	-
Q2 2018	341.76	52.59	-
Q3 2018	345.96	58.31	-
Q4 2018	393.17	62.87	-
Q1 2019	396.75	65.87	-
Q2 2019	385.57	60.69	-
Q3 2019	384.03	59.26	-
Q4 2019	430.78	74.26	-
Q1 2020	425.64	68.31	-
Q2 2020	418.91	49.52	-
Q3 2020	490.26	58.80	-
Q4 2020	466.26	67.33	-
Q1 2021	466.09	68.04	-
Q2 2021	458.49	68.21	-
Q3 2021	464.53	66.45	-
Q4 2021	477.03	75.29	-
Q1 2022	490.92	76.05	-
Q2 2022	479.56	78.30	-
Q3 2022	475.20	73.95	-
Q4 2022	568.80	91.34	-
Q1 2023	569.92	94.30	-
Q2 2023	536.21	91.12	-
Q3 2023	549.93	90.96	-
Q4 2023	656.49	116.57	-
Q1 2024	606.41	116.37	-
Q2 2024	578.15	112.14	-

Period	Medical Services	Pharmaceutical Products	Administration Fees
2014	718.55	185.23	-
2015	810.12	189.96	-
2016	1,044.39	198.83	-
2017	1,289.59	217.55	-
2018	1,441.68	235.34	-
2019	1,597.13	260.08	-
2020	1,801.07	243.96	-
2021	1,866.15	277.98	-
2022	2,014.48	319.64	-
2023	2,312.55	392.95	-

Analysts Estimates (Million)

Item	Q2 2024 (e)	Q2 2024 (a)	Change‬
Average	168.48	152.70	(9.4 %)

Estimates vs Actual (Million)

Item	Q2 2024 (e)	Q2 2024 (a)	Change
AlJazira Capital	152.50	152.70	0.1 %
Al Rajhi Capital	159.00	152.70	(4.0) %
Riyad Capital	165.00	152.70	(7.5) %
OSOOL AND BAKHEET	167.12	152.70	(8.6) %
U-Capital	167.20	152.70	(8.7) %
Sico	168.00	152.70	(9.1) %
Hermes	170.00	152.70	(10.2) %
SNB Capital	171.00	152.70	(10.7) %
Goldman Sachs	172.00	152.70	(11.2) %
YAQEEN	193.00	152.70	(20.9) %

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Mouwasat H1 2024 profit rises 2% to SAR 324.3M; Q2 at SAR 152.7M

Financials (M)

Current Quarter Comparison (M)

View other reports

Share Price

Mouwasat Medical Services Co. (MOUWASAT)

Financial Ratios

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2024 Q2

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Popular Links

Quick Links

About Us

Join Us

Follow Us

Mouwasat H1 2024 profit rises 2% to SAR 324.3M; Q2 at SAR 152.7M

Financials (M)

Current Quarter Comparison (M)

View other reports

Share Price

Mouwasat Medical Services Co. (MOUWASAT)

Financial Ratios

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q2 2024

Revenue by Business Segment (Latest) 2024 Q2

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Popular Links

Quick Links

About Us

Join Us

Follow Us

Business Segments (Million)